Focused On-demand Library for FAS-associated death domain protein

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for protein-protein interfaces.


 

Fig. 1. The screening workflow of Receptor.AI

This process entails comprehensive molecular simulations of the target protein, individually and in complex with essential partner proteins, along with ensemble virtual screening that focuses on conformational mobility in both its free and complex states. Potential binding pockets are considered at the protein-protein interaction interface and in remote allosteric locations to address every conceivable mechanism of action.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q13158

UPID:
FADD_HUMAN

ALTERNATIVE NAMES:
FAS-associating death domain-containing protein; Growth-inhibiting gene 3 protein; Mediator of receptor induced toxicity

ALTERNATIVE UPACC:
Q13158; Q14866; Q6IBR4

BACKGROUND:
FAS-associated death domain protein, with alternative names such as FAS-associating death domain-containing protein, plays a pivotal role in the apoptotic process by recruiting caspase-8 or caspase-10 to activated Fas or TNFR-1 receptors. This action triggers a cascade of caspases that lead to cell death. It also enhances interferon-mediated antiviral responses, underscoring its importance in immune regulation.

THERAPEUTIC SIGNIFICANCE:
Given its association with diseases featuring autoimmune lymphoproliferative syndrome-like symptoms and its critical function in apoptosis and immune response, targeting FAS-associated death domain protein offers a promising avenue for developing novel treatments for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.